Data from the SURPASS-PEDS trials, which was simultaneously published in The Lancet , showed once-weekly subcutaneous tirzepatide (Mounjaro, Eli Lilly), a GIP/GLP-1 dual agonist, conferred significant reductions in both HbA1c and BMI at 30 weeks compared with placebo
Genetic Factors That May Influence Your GLP-1 Response The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761) variants that relate to GLP-1 and related signaling pathways
Hydration Protocol for Accelerated Weight Loss Dehydration represents one of the most overlooked dangers during aggressive Retatrutide protocols
Fifth Meeting of the Internatioal Society of Haematology 1:9, 1979
The American Society of Anesthesiologists recommends discussing GLP-1 cessation with your surgeon because these medications slow gastric emptyingthe rate at which food leaves your stomachwhich can complicate anesthesia and aspiration risk during general anesthesia
Proper counseling and gradual dose titration can help reduce these issues
